Last updated: 16 August 2024 at 5:09pm EST

Dr. Jaume Pons Ph.D. Net Worth




The estimated Net Worth of Jaume Pons is at least $11.6 Milione dollars as of 14 August 2024. Dr Pons owns over 1,937 units of ALX Oncology stock worth over $1,289,492 and over the last 4 years he sold ALXO stock worth over $9,029,264. In addition, he makes $1,280,467 as Pres e CEO & Director at ALX Oncology.

Dr D ALXO stock SEC Form 4 insiders trading

Dr has made over 22 trades of the ALX Oncology stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,937 units of ALXO stock worth $4,997 on 14 August 2024.

The largest trade he's ever made was selling 50,000 units of ALX Oncology stock on 16 April 2024 worth over $710,000. On average, Dr trades about 12,991 units every 48 days since 2020. As of 14 August 2024 he still owns at least 591,510 units of ALX Oncology stock.

You can see the complete history of Dr Pons stock trades at the bottom of the page.





Dr. Jaume Pons Ph.D. biography

Dr. Jaume Pons Ph.D. is the Pres, CEO & Director at ALX Oncology.

What is the salary of Dr D?

As the Pres e CEO & Director of ALX Oncology, the total compensation of Dr D at ALX Oncology is $1,280,467. There are no executives at ALX Oncology getting paid more.



How old is Dr D?

Dr D is 55, he's been the Pres e CEO & Director of ALX Oncology since . There are 4 older and 3 younger executives at ALX Oncology. The oldest executive at ALX Oncology Holdings Inc. is Dr. Corey S. Goodman Ph.D., 70, who is the Independent Exec. Chairman.

What's Dr D's mailing address?

Jaume's mailing address filed with the SEC is C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at ALX Oncology

Over the last 4 years, insiders at ALX Oncology have traded over $32,891,459 worth of ALX Oncology stock and bought 1,414,400 units worth $27,854,124 . The most active insiders traders include G. Walmsley Graham, Jack Nielsen e Capital Ix, Llc Vivo Capita.... On average, ALX Oncology executives and independent directors trade stock every 22 days with the average trade being worth of $89,694. The most recent stock trade was executed by Shelly Pinto on 14 August 2024, trading 564 units of ALXO stock currently worth $1,455.



What does ALX Oncology do?

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.



What does ALX Oncology's logo look like?

ALX Oncology Holdings Inc. logo

Complete history of Dr Pons stock trades at ALX Oncology

Data
#
Ditta
Persona
Trans.
Transazione
Azioni Prezzo per azione Prezzo totale Azioni dopo Fonte
14 Aug 2024 Jaume Pons
Presidente e CSO
Vendita 1,937 $2.58 $4,997
14 Aug 2024
591,510
11 Jul 2024 Jaume Pons
Presidente e CSO
Opzione 20,000 $0.99 $19,800
11 Jul 2024
613,447
1 Jul 2024 Jaume Pons
Presidente e CSO
Vendita 10,758 $5.82 $62,612
1 Jul 2024
593,447
4 Jun 2024 Jaume Pons
Presidente e CSO
Opzione 20,000 $0.99 $19,800
4 Jun 2024
624,205
6 May 2024 Jaume Pons
Presidente e CSO
Opzione 20,000 $0.99 $19,800
6 May 2024
624,205
16 Apr 2024 Jaume Pons
Presidente e CSO
Vendita 50,000 $14.20 $710,000
16 Apr 2024
604,205
4 Apr 2024 Jaume Pons
Presidente e CSO
Vendita 20,000 $11.15 $223,000
4 Apr 2024
628,359
29 Dec 2023 Jaume Pons
Presidente e CSO
Vendita 7,179 $15.04 $107,972
29 Dec 2023
618,359
30 Jun 2023 Jaume Pons
Presidente e CSO
Vendita 3,208 $7.34 $23,547
30 Jun 2023
536,538
29 Dec 2022 Jaume Pons
Presidente e CSO
Vendita 3,232 $11.07 $35,778
29 Dec 2022
539,746
3 Feb 2022 Jaume Pons
Presidente e CSO
Opzione 24,154 $1.46 $35,265
3 Feb 2022
468,978
19 Oct 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $54.29 $906,643
19 Oct 2021
444,598
19 Oct 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $54.29 $906,643
19 Oct 2021
444,598
20 Sep 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $74.38 $1,242,146
20 Sep 2021
461,298
19 Aug 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $61.28 $1,023,376
19 Aug 2021
477,998
19 Jul 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $54.57 $911,319
19 Jul 2021
494,546
21 Jun 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $58.59 $978,453
21 Jun 2021
511,246
19 May 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $55.71 $930,357
19 May 2021
527,946
19 Apr 2021 Jaume Pons
Presidente e CSO
Vendita 16,700 $57.63 $962,421
19 Apr 2021
544,646
25 Mar 2021 Jaume Pons
Presidente e CSO
Opzione 10,000 $0.99 $9,900
25 Mar 2021
561,346
22 Mar 2021 Jaume Pons
Presidente e CSO
Opzione 16,700 $1.91 $31,897
22 Mar 2021
568,046
26 Jan 2021 Jaume Pons
Presidente e CSO
Opzione 10,000 $0.99 $9,900
26 Jan 2021
551,346


ALX Oncology executives and stock owners

ALX Oncology executives and other stock owners filed with the SEC include: